CD229 Double Nickase Plasmid (h): sc-404895-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD229 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD229 Double Nickase Plasmid (h) and CD229 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LY9. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD229 Antibody (HLy 9.1.25): sc-58992
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD229 Double Nickase Plasmid (h) | sc-404895-NIC | 20 µg | $410.00 | |||
CD229 Double Nickase Plasmid (h2) | sc-404895-NIC-2 | 20 µg | $410.00 |
LY9 encodes CD229 (SLAMF3), an immunoregulatory receptor of the SLAM family expressed predominantly on lymphocytes, where it mediates homophilic interactions that shape activation thresholds, cytokine production, and intercellular communication. Through association with adaptor proteins such as SAP/SH2D1A and downstream Src-family kinase signaling, CD229 contributes to modulation of T cell and B cell responses and influences immune synapse organization. Altered LY9/CD229 signaling has been implicated in immune dysregulation, with reported associations to autoimmune phenotypes and lymphoid malignancy biology. As a surface receptor with context-dependent activating and inhibitory effects, CD229 is frequently studied in pathways governing lymphocyte differentiation, exhaustion, and antigen receptor co-signaling.
CD229 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LY9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LY9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LY9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LY9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.